This is consistent with another report conducted in CLL patients, which revealed that resistance to fludarabine was linked to overexpression of UGCG and that treatment with a UGCG inhibitor (UGCGi) restored sensitivity to fludarabine-resistant cells in vitro [13]. This evidence concerns the gene UGCG and B-cell chronic lymphocytic leukemia.